📰 Local Coverage Determination News
Local Coverage Determination News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Local Coverage Determination. Real-time updates on events, politics, business and more.
February 29, 2024
Renalytix receives U.S. Government approval for kidneyintelX.dkd inclusion in a 10-year contract for early-stage kidney disease testing services at $950 per result. Medicare coverage pending final policy approval.
February 20, 2024
On February 6, 2024, the US Centers for Medicare & Medicaid Services (CMS) released a set of frequently asked questions (FAQs) related to Medicare Advantage (MA) coverage criteria and...
February 15, 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 -- Renalytix plc , an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today...
February 15, 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled...
February 13, 2024
Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than-expected fourth-quarter financial results.
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ:IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter fin...
February 9, 2024
/PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest kidney patient organization in the nation, issued an Official...
January 16, 2024
NeXT Dx helps clinicians make informed, personalized cancer treatment selections and match patients with clinical trials Access to NeXT Dx expands to the 66 million Medicare and Medicare Advantage...
January 16, 2024
Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation's 66...